Analysis of Competing Risks of Cardiovascular Death in Patients with Hepatocellular Carcinoma: A Population-based Study

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2023 Dec 22

PMID 38134062

Authors

Lizhi Cao

Xiaoying Wang

Yuzhong Yan

Zhongping Ning

Linlin Ma

Yanfei Li

Affiliations

Soon will be listed here.

Abstract

Clinical data has shown that cardiovascular diseases (CVDs) have emerged as a prominent cause of mortality in individuals with hepatocellular carcinoma (HCC). This research aimed to reveal the comorbid effects of CVDs in patients with HCC. The cardiovascular mortality of patients diagnosed with HCC between 2000 and 2014 was compared to that of the general US population. Standardized mortality ratios were calculated to quantify the relative risk of cardiovascular mortality in HCC patients. The cumulative incidence of cardiovascular death (CVD) was estimated using Fine-Gray testing, and independent risk factors for CVD were determined using competing risk models. The results were analyzed using the Kaplan-Meier analysis. The overall SMR for CVD in HCC patients was 11.15 (95% CI: 10.99-11.32). The risk of CVD was significantly higher in patients aged < 55 years (SMR: 56.19 [95% CI: 54.97-57.44]) compared to those aged ≥ 75 years (SMR: 1.86 [95% CI: 1.75-1.97]). This study suggests that patients with HCC are at significant risk of developing CVD. Competing risk analyses indicated that age, grade, tumor size, surveillance, epidemiology, and end results stage, and surgical status were independent risk factors for CVD in patients with HCC. Therefore, patients with HCC require enhanced preventive screening and management of CVDs during and after treatment to improve patient survival.

Citing Articles

Surgical Implications for Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma.

Anbarasu C, Williams-Perez S, Camp E, Erstad D Cancers (Basel). 2024; 16(16).

PMID: 39199546 PMC: 11352989. DOI: 10.3390/cancers16162773.

References

Elshanbary A, Zaazouee M, Abdelmonem M, Mohammed Y, Abdel-Aziz W . Risk factors for cardiovascular mortality and melanoma-specific mortality among patients with melanoma: a SEER based study. Eur J Cancer Prev. 2021; 31(3):293-300. DOI: 10.1097/CEJ.0000000000000690. View

Lagergren J, Bottai M, Santoni G . Patient Age and Survival After Surgery for Esophageal Cancer. Ann Surg Oncol. 2020; 28(1):159-166. PMC: 7752878. DOI: 10.1245/s10434-020-08653-w. View

Wei F . Does an extreme age (≥80 years) affect outcomes in patients after liver cancer surgery? A meta-analysis. ANZ J Surg. 2018; 89(1-2):25-31. DOI: 10.1111/ans.14676. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Large M, Reichard C, Williams J, Chang C, Prasad S, Leung Y . Incidence, risk factors, and complications of postoperative delirium in elderly patients undergoing radical cystectomy. Urology. 2012; 81(1):123-8. DOI: 10.1016/j.urology.2012.07.086. View

Fuster J . Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors. Thromb Res. 2022; 213 Suppl 1:S107-S112. DOI: 10.1016/j.thromres.2021.12.009. View

Yeh E . Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med. 2006; 57:485-98. DOI: 10.1146/annurev.med.57.121304.131240. View

Kiran R, Attaluri V, Hammel J, Church J . A novel nomogram accurately quantifies the risk of mortality in elderly patients undergoing colorectal surgery. Ann Surg. 2012; 257(5):905-8. DOI: 10.1097/SLA.0b013e318269d337. View

Burra P, Becchetti C, Germani G . NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep. 2020; 2(6):100192. PMC: 7607500. DOI: 10.1016/j.jhepr.2020.100192. View

10.

Wolfe J, Wolfe N, Rich M . Perioperative care of the geriatric patient for noncardiac surgery. Clin Cardiol. 2019; 43(2):127-136. PMC: 7021644. DOI: 10.1002/clc.23302. View

11.

Wang S, Ge C, Zhang J . Cardiovascular Mortality Risk in Patients with Bladder Cancer: A Population-Based Study. J Cardiovasc Dev Dis. 2022; 9(8). PMC: 9409417. DOI: 10.3390/jcdd9080255. View

12.

Armenian S, Xu L, Ky B, Sun C, Farol L, Pal S . Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016; 34(10):1122-30. PMC: 7357493. DOI: 10.1200/JCO.2015.64.0409. View

13.

Cardinale D, Iacopo F, Cipolla C . Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020; 7:26. PMC: 7093379. DOI: 10.3389/fcvm.2020.00026. View

14.

Renu K, V G A, P B T, Arunachalam S . Molecular mechanism of doxorubicin-induced cardiomyopathy - An update. Eur J Pharmacol. 2017; 818:241-253. DOI: 10.1016/j.ejphar.2017.10.043. View

15.

Lu Z, Teng Y, Ning X, Wang H, Feng W, Ou C . Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors. Cancer. 2022; 128(18):3330-3339. DOI: 10.1002/cncr.34375. View

16.

Lonardo A, Sookoian S, Pirola C, Targher G . Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 2015; 65(8):1136-50. DOI: 10.1016/j.metabol.2015.09.017. View

17.

Lyon A, Lopez-Fernandez T, Couch L, Asteggiano R, Aznar M, Bergler-Klein J . 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022; 23(10):e333-e465. DOI: 10.1093/ehjci/jeac106. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Nevola R, Acierno C, Pafundi P, Adinolfi L . Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management. Minerva Med. 2020; 112(2):188-200. DOI: 10.23736/S0026-4806.20.07129-3. View

20.

Berzigotti A, Erice E, Gilabert R, Reverter E, Abraldes J, Garcia-Pagan J . Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis. Am J Gastroenterol. 2012; 108(1):75-82. DOI: 10.1038/ajg.2012.362. View